ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.
Hiroya Takiuchi
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yasutsuna Sasaki
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Tomohiro Nishina
Honoraria - Taiho Pharmaceutical
Hirofumi Yasui
Honoraria - Taiho Pharmaceutical
Kei Muro
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Akihito Tsuji
Honoraria - Taiho Pharmaceutical
Other Remuneration - Taiho Pharmaceutical
Wasaburo Koizumi
Honoraria - Taiho Pharmaceutical
Yasushi Toh
Honoraria - Taiho Pharmaceutical
Takuo Hara
Honoraria - Taiho Pharmaceutical
Yoshinori Miyata
Honoraria - Taiho Pharmaceutical